Assessment Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: In combination with chemotherapy, with the remedy of adult patients with regionally recurrent unresectable or metastatic triple-unfavorable breast cancer which have not gained prior chemotherapy for metastatic sickness and whose tumours Convey programmed mobile Dying-ligand one (merged beneficial rating ≥ ... https://judym912gij6.lotrlegendswiki.com/user